SCHEMBL6208280

SCHEMBL6208280

CCOC(=O)C(Nc1ccc(Oc2ccc3c(cnn3C)c2)nc1)C(=O)OCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.46
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
CACNA1H O95180 1/20 0.40
CHRNA7 P36544 2/20 0.40
MAOB P27338 3/20 0.39
MAOA P21397 2/20 0.39
ACHE P22303 1/20 0.39
TRPM5 Q9NZQ8 1/20 0.39
MAPT P10636 3/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
ACACB O00763 2/20 0.37
ACACA Q13085 1/20 0.37
PDE1C Q14123 1/20 0.37
SCN9A Q15858 1/20 0.37
ROCK1 Q13464 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6209201 0.85 SMO (0.49)
SCHEMBL6208624 0.85 NOTUM (0.39) NOTUMCCNCCDK8CACNA1HCHRNA7
SCHEMBL6208908 0.83 SMO (0.48) MAPTRAB9A
SCHEMBL6209292 0.82 PGR (0.41) P2RX3
SCHEMBL6205298 0.78 CA12 (0.44) MAPTCA12CA1CA2CA9
SCHEMBL6210556 0.72 NR3C1 (0.47)
SCHEMBL6211896 0.72 MMP13 (0.41) CCNCCDK8CACNA1HSCN9A
SCHEMBL6209850 0.71 KDM4E (0.52) NOTUMTRPM5PDE1CALDH1A1RAB9A
SCHEMBL6208913 0.70 SMO (0.44) MAPT
SCHEMBL6211088 0.70 HSPB1 (0.55) MAPTALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501833-B1 N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-11-02 EP disclosed
US-6900201-B2 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-05-31 US disclosed
EP-1501833-A1 N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-02 EP disclosed
US-20040010141-A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2004-01-15 US disclosed
WO-2003091258-A1 N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010141-A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP9, MMP8, MMP2 NOTUM 3479/4885CCNC 1078/4885CDK8 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.